Fabino Enterprises Ltd

The next results date for Fabino Enter is 13 November 2025.

As of October 8, 2025, Fabino Enter is considered very expensive and overvalued, with a PE ratio of 4.83 and disappointing financial performance, including a year-to-date stock return of -30.09%, compared to the Sensex's 4.65% return.

As of September 23, 2025, Fabino Enter is considered very expensive and overvalued with a PE ratio of 5.09, an EV to EBIT of 6.49, and a Price to Book Value of 1.19, especially compared to peers like Sun Pharma and Divi's Lab, while also underperforming the Sensex with a year-to-date return of -26.29%.

As of September 22, 2025, Fabino Enter is considered expensive but still overvalued with a PE Ratio of 5.35, significantly lower than its peers, and has underperformed the Sensex with a year-to-date return of -22.55%.

As of September 18, 2025, Fabino Enter is considered very expensive with a low PE ratio of 5.35 and a PEG ratio of 0.00, indicating it is overvalued and lacks growth potential compared to peers like Sun Pharma and Divi's Lab, while also underperforming in the market with a year-to-date return of -22.55%.

As of September 17, 2025, Fabino Enter is considered overvalued with a valuation grade of expensive, a PE ratio of 5.35, and a year-to-date return of -22.55%, underperforming against the Sensex, despite being relatively cheaper than peers like Sun Pharma and Divi's Lab.

As of September 16, 2025, Fabino Enter is considered very expensive and overvalued despite a low PE ratio of 5.35 compared to peers, with a year-to-date return of -22.55% against the Sensex's positive 5.43%.

As of September 15, 2025, Fabino Enter is considered overvalued with a PE ratio of 5.35 and a year-to-date return of -22.55%, significantly lower than its peers like Sun Pharma and Divi's Laboratories, which have much higher PE ratios.

As of August 11, 2025, Fabino Enter is considered very expensive and overvalued, with a PE ratio of 5.46, an EV to EBIT of 6.27, and a ROE of 3.13%, significantly higher than peers like Sun Pharma and Divi's Lab, while also underperforming the Sensex with a year-to-date return of -20.97%.

As of August 8, 2025, Fabino Enter is considered overvalued with a PE ratio of 5.46, an EV to EBIT of 6.27, and a ROE of 3.13%, significantly lower than its peers, while its stock has underperformed the Sensex with a year-to-date return of -20.97%.

As of August 8, 2025, Fabino Enter is considered overvalued with a PE ratio of 5.46 and an EV to EBIT of 6.27, significantly lower than its peers like Sun Pharma and Divi's Lab, and has underperformed the Sensex with a year-to-date return of -20.97%.

As of August 8, 2025, Fabino Enter is considered overvalued with a PE Ratio of 5.46, an EV to EBIT of 6.27, and a ROE of 3.13%, despite being lower than its peers, and has underperformed the Sensex with a year-to-date return of -20.97%.

As of 18th July, Fabino Enterprises Ltd has a market capitalization of 5.00 Cr, with recent net sales of 1.13 Cr and a net profit of 0.01 Cr for the quarter ending June 2021. The balance sheet for March 2024 shows shareholder's funds of 4.14 Cr and total assets of 15.35 Cr.

Fabino Enterprises Ltd is a micro-cap pharmaceutical company, incorporated in 2011, with recent net sales of 11 Cr and a market cap of 6 Cr. It has a P/E ratio of 5.00 and a debt-equity ratio of 0.20.

The top shareholder of Fabino Enter is promoter Aditya Mahavir Jain, holding 52.38%. The highest public shareholder is Nopea Capital Services Private Limited at 4.71%, while individual investors collectively own 29.18% of the shares.

Fabino Enter's peers include Unjha Formul., Beryl Drugs, Cian Healthcare, Adline Chem Lab, Ortin Global, Vivanza Biosci., Ganga Pharma., Brawn Biotech, and Shyama Computro. Unjha Formul. shows excellent management risk and the highest 1-year return at 23.34%, while Fabino Enter has average management risk and a 1-year return of -12.24%.

As of June 12, 2025, Fabino Enter is considered very expensive and overvalued with a PE ratio of 5.20, significantly lower than its peers like Sun Pharma and Divi's Lab, while also underperforming the Sensex with a year-to-date return of -24.77%.

As of June 12, 2025, Fabino Enter is considered very expensive and overvalued with a PE ratio of 5.20, significantly lower than its peers like Sun Pharma and Divi's Lab, while also underperforming the Sensex with a year-to-date return of -24.77%.

As of June 12, 2025, Fabino Enter is considered very expensive and overvalued with a PE ratio of 5.20, significantly lower than its peers like Sun Pharma and Divi's Lab, while also underperforming the Sensex with a year-to-date return of -24.77%.